In this minisode, Ryan is joined by Vynamic’s Brian Schachter to discuss a few recent newsworthy items including: the Medicare reimbursement for biosimilars (00:32), 2023 Medicare Advantage Star Ratings and overall sentiment of the US Healthcare system (03:51), drug price increases outpacing inflation (10:18), and Mark Cuban’s Cost Plus Drug Company partnering with Capital Blue Cross (11:48). 

Podcast Tags: healthcare, healthcare news, life sciences, Inflation Reduction Act, biosimilars, Medicare, , drug pricing, healthcare access, Mark Cuban, Capital Blue Cross 

Source Links:  

• https://www.cms.gov/files/document/10522-inflation-reduction-act-timeline.pdf) 
• https://www.fiercepharma.com/pharma/nearing-watershed-year-biosimilars-industry-should-get-boost-new-measure-inflation-reduction 
• https://healthpayerintelligence.com/news/ma-part-d-contracts-see-lower-2023-medicare-advantage-star-ratings 
• https://www.fiercehealthcare.com/providers/poll-gallup-and-west-health-shows-75-americans-grade-affordability-us-healthcare-d-or-f 
• https://www.fiercehealthcare.com/payers/medicare-advantage-star-ratings-show-steep-declines-2023-pandemic-flexibilities-go-away#:~:text=Payers-,Medicare%20Advantage%20star%20ratings%20show%20steep%20declines,as%20pandemic%20flexibilities%20go%20away&text=Approximately%2051%25%20of%20Medicare%20Advantage,rating%20or%20higher%20for%202022. 
• https://www.fiercehealthcare.com/payers/hhs-more-1200-drugs-rose-their-prices-past-inflation-2021 
• https://www.fiercehealthcare.com/payers/mark-cuban-cost-plus-drug-company-bags-first-health-plan-partner 

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 

1-888-VYNAMIC. 

Mindy McGrath, Healthcare Industry Advisor  

[email protected] 

Ryan Hummel, Executive and Head of Provider Sector 

[email protected] 

Brian Schachter, Director 

[email protected]